Cellectar Biosciences, Inc. clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 1 with a minor change only.

1. Notable

   Novel Targeted Radiotherapy · Inoperable Relapsed or Refractory HGG

   Primary completion pushed from May 2026 to Jun 30, 2027

   Also in this update: Study completion pushed from Sep 2026 to Dec 2027

   Cellectar Biosciences, Inc.·Phase 1· NCT05610891· Registry history of NCT05610891 on ClinicalTrials.gov (opens the registry)

   Oct 1, 2026

2. Notable

   CLOVER-2 · CLR 131 in Pediatric Relapsed/Refractory Malignant…CLOVER-2 · CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

   Primary completion pushed from Aug 25, 2026 to Jun 30, 2027

   Also in this update: Study completion pushed from Feb 25, 2027 to Dec 2027

   Cellectar Biosciences, Inc.·Phase 1· NCT03478462· Registry history of NCT03478462 on ClinicalTrials.gov (opens the registry)

   Oct 1, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.